Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Pre-Mkt 12-16 08:15:32 EST

2.17

+0.19

+9.60%

盘前2.18

+0.01+0.46%

08:11 EST

High2.26	Low1.98	Vol4.02M
Open2.00	D1 Closing1.98	Amplitude14.14%
Mkt Cap96.39M	Tradable Cap52.84M	Total Shares44.42M
T/O8.61M	T/O Rate16.51%	Tradable Shares24.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":2.17,"timestamp":1765832400000,"preClose":1.98,"halted":0,"volume":4019712,"hourTrading":{"tag":"盘前","latestPrice":2.18,"preClose":2.17,"latestTime":"08:11 EST","volume":9058,"amount":19644.609964,"timestamp":1765890690953},"delay":0,"floatShares":24350594,"shares":44419529,"eps":-1.501597,"marketStatus":"Pre-Mkt","change":0.19,"latestTime":"12-16 08:15:32 EST","open":2,"high":2.26,"low":1.98,"amount":8614982.443008,"amplitude":0.141414,"askPrice":2.3,"askSize":1500,"bidPrice":1.98,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.501597,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.17,"preHourTrading":{"tag":"盘前","latestPrice":2.18,"preClose":2.17,"latestTime":"08:11 EST","volume":9058,"amount":19644.609964,"timestamp":1765890690953},"postHourTrading":{"tag":"盘后","latestPrice":2.1635,"preClose":2.17,"latestTime":"19:50 EST","volume":19673,"amount":42969.4599,"timestamp":1765846202085},"volumeRatio":2.1651512575168783,"impliedVol":4.7303,"impliedVolPercentile":0.9398},"requestUrl":"/m/hq/s/OTLK/wiki","defaultTab":"wiki","newsList":[{"id":"2583680037","title":"H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680037?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:39","pubTimestamp":1763163566,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Outlook Therapeutics, with a price target of $1.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-outlook-therapeutics-otlk-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-hold-rating-for-outlook-therapeutics-otlk-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK"],"gpt_icon":0},{"id":"2583593112","title":"Outlook Therapeutics announces acceptance of BLA for ONS-5010","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593112","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593112?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:35","pubTimestamp":1763040944,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has acknowledged receipt of the resubmission of the Biologic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-for-ons-5010-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-announces-acceptance-of-bla-for-ons-5010-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","OTLK","LENZ","BK4007"],"gpt_icon":0},{"id":"2583593378","title":"Outlook Therapeutics Inc - FDA Sets Pdufa Goal Date of December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593378?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5XQJTH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2583593302","title":"Outlook Therapeutics Inc:  Ons-5010, IF Approved, Will Be Branded as Lytenava for Treatment of Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593302?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA5XQJTH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2580215062","title":"Outlook Therapeutics Inc - IF Approved, Ons-5010 to Be Branded as Lytenava for Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215062?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:35","pubTimestamp":1762176900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUABZCKPP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2571510354","title":"Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2571510354","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571510354?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:33","pubTimestamp":1759170784,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) said Monday it expects to resubmit its biologics license application for ONS-5010, an investigational treatment for wet macular degeneration, after completing a Type A meet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","OTLK","BK4539","BK4007"],"gpt_icon":0},{"id":"2571339031","title":"BRIEF-Outlook Therapeutics Provides Update On Type A Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2571339031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571339031?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:21","pubTimestamp":1759152072,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Provides Update On Type A Meeting With FDASept 29 (Reuters) - Outlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS PROVIDES UPDATE ON TYPE A MEETING WITH FDAOUTLOOK THERAPEU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6DZRJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2571533522","title":"Outlook Therapeutics Provides Update on Type a Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2571533522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571533522?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:45","pubTimestamp":1759149900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6DZRJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2571433577","title":"Outlook Therapeutics Inc - to Resubmit Bla by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571433577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571433577?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:45","pubTimestamp":1759149900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA6DZRJP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2569420436","title":"U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2569420436","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569420436?lang=en_us&edition=fundamental","pubTime":"2025-09-22 15:58","pubTimestamp":1758527890,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, TeslaSept 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apple, GE Aerosp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nL5N3V90BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251132253.USD","TSYW.SI","LU0444973449.USD","LU0868494617.USD","IE00BZ1G4Q59.USD","SG9999014880.SGD","SG9999015986.USD","BK4576","AAPL","LU1861215975.USD","IE00B3SWFQ91.USD","SG9999002224.SGD","CRC","LU2381873111.SGD","BK4505","JSPR","LU0215105999.USD","LU1974910355.USD","LU2361044949.HKD","LU0127658192.USD","LU0048584097.USD","LU0210533765.USD","SINT","LU1674673428.USD","MACW.SI","LU1084165304.USD","GB00BDT5M118.USD","LU0642271901.SGD","NDRA","LU0096364046.USD","GRI","LU0203201768.USD","IE0009356076.USD","MTN","LU2191332357.HKD","OTLK","BK4543","LU0345770993.USD","LU1003077747.HKD","RBLX","WEC","URI","LEN","IRM","TSLA","LU0072462426.USD","LU0316494557.USD","GE"],"gpt_icon":1},{"id":"2569272296","title":"Outlook Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $8 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2569272296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569272296?lang=en_us&edition=fundamental","pubTime":"2025-09-22 10:45","pubTimestamp":1758509101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V70RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2565595186","title":"Outlook Therapeutics Announces Departure of Chief Commercial Officer Jeff Evanson","url":"https://stock-news.laohu8.com/highlight/detail?id=2565595186","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565595186?lang=en_us&edition=fundamental","pubTime":"2025-09-06 05:01","pubTimestamp":1757106105,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc. announced that Jeff Evanson has stepped down as the Chief Commercial Officer, effective September 5, 2025. His departure is classified as a termination of employment without cause.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL1v9HJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2564812773","title":"BRIEF-Outlook Therapeutics Requests Type A Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2564812773","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564812773?lang=en_us&edition=fundamental","pubTime":"2025-09-03 00:58","pubTimestamp":1756832291,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Requests Type A Meeting With FDAOutlook Therapeutics Inc OTLK.O:OUTLOOK THERAPEUTICS REQUESTS TYPE A MEETING WITH FDAOUTLOOK THERAPEUTICS INC: TYPE A MEETING REQUEST HAS BEE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3TCWBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2564807818","title":"Outlook Therapeutics Requests Type a Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564807818?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:35","pubTimestamp":1756816500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA3TCWBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2563076212","title":"Outlook Therapeutics Shares Fall After HC Wainwright Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2563076212","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563076212?lang=en_us&edition=fundamental","pubTime":"2025-08-30 02:34","pubTimestamp":1756492446,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  shares were down more than 17% in recent Friday trading after HC Wainwright downgraded the stock to neutral from buy and cut its price target to $1.00 from $3.00.Trading volume stood at more than 14.7 million shares against a daily average of roughly 2.5 million.Price: 0.90, Change: -0.20, Percent Change: -17.89","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","LENZ"],"gpt_icon":0},{"id":"2563186047","title":"BUZZ-U.S. STOCKS ON THE MOVE-Caterpillar, Dell, Dollar Tree","url":"https://stock-news.laohu8.com/highlight/detail?id=2563186047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563186047?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:37","pubTimestamp":1756467470,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Caterpillar, Dell, Dollar TreeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nL6N3UL0HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774391.USD","S","BK4604","IE00B19Z9P08.USD","LU2272731782.SGD","LU1064131342.USD","LU1261432733.SGD","LU0426417589.USD","LU2247934214.USD","LU1429558221.USD","LU1046421795.USD","BK4534","IE00B19Z9Z06.USD","BK4097","IE00BZ9MQY76.HKD","CAT","LU1992135399.USD","LU2473716301.USD","LU1235294995.USD","BK4141","LU0274383776.USD","LU2125910179.SGD","LU1043141396.HKD","LU0127658192.USD","GAP","LU2125910336.SGD","BK4561","LU0107464264.USD","ADSK","BK4094","DELL","LU1989764664.SGD","LU0345774631.USD","DLTR","BK4520","LU1988902786.USD","IE00BMPRXR70.SGD","LU0976567544.SGD","LU1084165304.USD","LU0006061336.USD","LU1803068623.USD","IE00B894F039.SGD","LU1861215975.USD","LU1861220033.SGD","LU2238339852.HKD","LU0868494617.USD","BK4170","SG9999000418.SGD","OTLK"],"gpt_icon":1},{"id":"2563478600","title":"HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2563478600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563478600?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:25","pubTimestamp":1756466758,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) has an average rating of overweight and mean price target of $8.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","LENZ"],"gpt_icon":0},{"id":"2563042085","title":"BUZZ-Outlook falls as Wainwright downgrades stock after US FDA declines to approve eye drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2563042085","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563042085?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:21","pubTimestamp":1756466464,"startTime":"0","endTime":"0","summary":"BUZZ-Outlook falls as Wainwright downgrades stock after US FDA declines to approve eye drug** Shares of drugmaker Outlook Therapeutics OTLK.O fall 6.4% to $1.02 premarket after closing 54.1% lower on Thursday, hitting record low** U.S. FDA declined to approve co's eye drug, ONS-5010 ** H.C. Wainwright downgrades stock to \"neutral\" from \"buy,\" with a $1 PT** Brokerage says it hoped FDA might show some flexibility since ONS-5010 achieved non-inferiority to Roche's ROG.S Lucentis in key trial, in which the drug missed main goal**  Another late-stage study will be needed, H.C. Wainwright says, adding OTLK has demonstrated ONS-5010 works and another study would have high probability of success, but co's cash position complicates matters** OTLK indicated that commercialization of the drug approved in Europe would be its focus** \"Removed all future U.S. revenues from our valuation and move to sidelines till further clarity ... assume the company will raise additional capitals to support opera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nL4N3UL0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK"],"gpt_icon":0},{"id":"2563523044","title":"Outlook Therapeutics Inc : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2563523044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563523044?lang=en_us&edition=fundamental","pubTime":"2025-08-29 18:53","pubTimestamp":1756464790,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nFWN3UL0W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2563697070","title":"Outlook Therapeutics Is Maintained at Neutral by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2563697070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563697070?lang=en_us&edition=fundamental","pubTime":"2025-08-29 04:48","pubTimestamp":1756414080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OTLK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 28, 2025 16:48 ET (20:48 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","OTLK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.085},{"period":"1month","weight":0.3822},{"period":"3month","weight":1.0093},{"period":"6month","weight":0.2917},{"period":"1year","weight":0.4662},{"period":"ytd","weight":0.1481}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.117155},{"month":2,"riseRate":0.444444,"avgChangeRate":0.160578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.4,"avgChangeRate":-0.074188}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction